These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 18001616)

  • 21. Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Amarenco P; Goldstein LB; Sillesen H; Benavente O; Zweifler RM; Callahan A; Hennerici MG; Zivin JA; Welch KM;
    Stroke; 2010 Mar; 41(3):426-30. PubMed ID: 20110538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ischemic stroke: a cardiovascular risk equivalent? Lessons learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Fitchett DH; Goodman SG; Langer A
    Can J Cardiol; 2008 Sep; 24(9):705-8. PubMed ID: 18787721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statins and stroke prevention.
    Paciaroni M; Hennerici M; Agnelli G; Bogousslavsky J
    Cerebrovasc Dis; 2007; 24(2-3):170-82. PubMed ID: 17596685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of intensive treatment with atorvastatin versus standard doses of statins on the risk of stroke. A meta-analysis from five randomized trials including 25,709 patients].
    Fernándezde Bobadilla J; Moreno R; Fernández C; Martínez A; Sánchez-Maestre C; Ezpeleta-Echevarri D
    Rev Neurol; 2009 Jun 1-15; 48(11):561-5. PubMed ID: 19472152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A systematic review and economic evaluation of statins for the prevention of coronary events.
    Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
    Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study.
    Goldstein LB; Amarenco P; Lamonte M; Gilbert S; Messig M; Callahan A; Hennerici M; Sillesen H; Welch KM;
    Stroke; 2008 Sep; 39(9):2444-8. PubMed ID: 18617654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose statin therapy for secondary prevention of stroke: stroke prevention by aggressive reduction in cholesterol levels study review.
    Schwertz DW; Badellino KO
    J Cardiovasc Nurs; 2008; 23(1):8-13. PubMed ID: 18158500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expanding roles for atorvastatin.
    Singh V; Deedwania P
    Drugs Today (Barc); 2008 Jun; 44(6):455-71. PubMed ID: 18596999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack.
    Byun YS; Yang X; Bao W; DeMicco D; Laskey R; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2017 Jan; 69(2):147-158. PubMed ID: 28081824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
    Wanner C; Krane V; März W; Olschewski M; Mann JF; Ruf G; Ritz E;
    N Engl J Med; 2005 Jul; 353(3):238-48. PubMed ID: 16034009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intestinal cholesterol absorption, treatment with atorvastatin, and cardiovascular risk in hemodialysis patients.
    Silbernagel G; Fauler G; Genser B; Drechsler C; Krane V; Scharnagl H; Grammer TB; Baumgartner I; Ritz E; Wanner C; März W
    J Am Coll Cardiol; 2015 Jun; 65(21):2291-8. PubMed ID: 26022817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
    Sever PS; Poulter NR; Dahlof B; Wedel H;
    J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.
    Plosker GL; Lyseng-Williamson KA
    Pharmacoeconomics; 2007; 25(12):1031-53. PubMed ID: 18047388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial.
    Zhao SP; Yu BL; Peng DQ; Huo Y
    Atherosclerosis; 2014 Apr; 233(2):707-712. PubMed ID: 24603217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose atorvastatin after stroke or transient ischemic attack.
    Amarenco P; Bogousslavsky J; Callahan A; Goldstein LB; Hennerici M; Rudolph AE; Sillesen H; Simunovic L; Szarek M; Welch KM; Zivin JA;
    N Engl J Med; 2006 Aug; 355(6):549-59. PubMed ID: 16899775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial.
    Durazzo AE; Machado FS; Ikeoka DT; De Bernoche C; Monachini MC; Puech-Leão P; Caramelli B
    J Vasc Surg; 2004 May; 39(5):967-75; discussion 975-6. PubMed ID: 15111846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High dose atorvastatin after stroke or transient ischaemic attack (SPARCL)--does every stroke patient in Pakistan deserve a statin?
    Khan M; Kamran KA
    J Pak Med Assoc; 2010 Jun; 60(6):505-6. PubMed ID: 20527658
    [No Abstract]   [Full Text] [Related]  

  • 38. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
    Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin.
    Bybee KA; Lee JH; O'Keefe JH
    Curr Med Res Opin; 2008 Apr; 24(4):1217-29. PubMed ID: 18358084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cost-effectiveness analysis of using high doses of atorvastatin for the secondary stroke prevention in Spain].
    Arrospide A; Mar J; Vivancos-Mora J; Rejas-Gutiérrez J; Caro J
    Rev Neurol; 2010 Jul; 51(1):1-11. PubMed ID: 20568062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.